Abstract
Background: Persistent müllerian duct syndrome (PMDS) is characterized by the persistence of müllerian duct derivatives in otherwise normally virilized 46,XY males. Biallelic mutations of the anti-müllerian hormone (AMH) and AMH receptor type 2 (AMHR2) genes lead to PMDS type 1 and 2, respectively. Aim: The aims of the study were to report the clinical, hormonal, and genetic findings in a patient with PMDS and discuss surgical strategies to achieve successful orchidopexy. Results: A 4-year-old boy was evaluated after the incidental finding of müllerian derivates during laparoscopy for nonpalpable gonads. Karyotype was 46,XY and laboratory tests revealed normal serum gonadotropin and androgen levels but undetectable serum AMH levels. PMDS was suspected. Molecular analysis revealed a novel variant c.902_929del in exon 5 and a previously reported mutation (c.367C>T) in exon 1 of the AMH gene. Successful orchidopexy was performed in two sequential surgeries in which the müllerian duct structure was preserved and divided to protect the vascular supply to the gonads. Histological evaluation of the testicular biopsy showed mild signs of dysgenesis. Doppler ultrasound showed blood flow in both testes positioned in the scrotum 1.5 years after surgery. Conclusion: PMDS is a rare entity that requires a high index of suspicion (from surgeons) when evaluating a patient with bilateral cryptorchidism. Surgical treatment is challenging and long-term follow-up is essential. Histological evaluation of the testis deserves further investigation.
Journal Section:
Original Article
References
1.
Behringer
RR
, Finegold
MJ
, Cate
RL
. Müllerian-inhibiting substance function during mammalian sexual development
. Cell
. 1994
;79
(3
):415
–25
.2.
Farikullah
J
, Ehtisham
S
, Nappo
S
, Patel
L
, Hennayake
S
. Persistent Müllerian duct syndrome: lessons learned from managing a series of eight patients over a 10-year period and review of literature regarding malignant risk from the Müllerian remnants
. BJU Int
. 2012 Dec
;110
(11c
):E1084
–9
.3.
Grinspon
RP
, Bedecarrás
P
, Ballerini
MG
, Iñiguez
G
, Rocha
A
; LAREP Group
, . Early onset of primary hypogonadism revealed by serum anti-Müllerian hormone determination during infancy and childhood in trisomy 21
. Int J Androl
. 2011
;34
(5 Pt 2
):e487
–98
.4.
Hedinger
E
. Histopathology of undescended testes
. Eur J Pediatr
. 1982
;139
(4
):266
–71
.5.
Hutson
JM
, Southwell
BR
, Li
R
, Lie
G
, Ismail
K
, Harisis
G
, . The regulation of testicular descent and the effects of cryptorchidism
. Endocr Rev
. 2013
;34
(5
):725
–52
.6.
Imbeaud
S
, Carré-Eusèbe
D
, Rey
R
, Belville
C
, Josso
N
, Picard
JY
. Molecular genetics of the persistent müllerian duct syndrome: a study of 19 families
. Hum Mol Genet
. 1994
;3
(1
):125
–31
.7.
Jespersen
K
, Ljubicic
ML
, Johannsen
TH
, Christiansen
P
, Skakkebaek
NE
, Juul
A
. Distinguishing between hidden testes and anorchia: the role of endocrine evaluation in infancy and childhood
. Eur J Endocrinol
. 2020 Jul
;183
(1
):107
–17
.8.
Josso
N
, Rey
RA
. What does AMH tell us in pediatric disorders of sex development
. Front Endocrinol
. 2020
;11
:619
.9.
Josso
N
, Rey
RA
, Picard
JY
. Anti-müllerian hormone: a valuable addition to the toolbox of the pediatric endocrinologist
. Int J Endocrinol
. 2013
;2013
:674105
.10.
Kelsey
TW
, Miles
A
, Mitchell
RT
, Anderson
RA
, Wallace
WHB
. A Normative Model of Serum Inhibin B in Young Males
. PLoS One
. 2016
;11
(4
):e0153843
.11.
Kolon
TF
, Herndon
CDA
, Baker
LA
, Baskin
LS
, Baxter
CG
, Cheng
EY
, ; American Urological Assocation
. Evaluation and treatment of cryptorchidism: AUA guideline
. J Urol
. 2014
;192
(2
):337
–45
.12.
Manjunath
BG
, Shenoy
VG
, Raj
P
. Persistent müllerian duct syndrome: how to deal with the müllerian duct remnants – a review
. Indian J Surg
. 2010
;72
(1
):16
–9
.13.
Matzuk
MM
, Finegold
MJ
, Mishina
Y
, Bradley
A
, Behringer
RR
. Synergistic effects of inhibins and müllerian-inhibiting substance on testicular tumorigenesis
. Mol Endocrinol
. 1995
;9
(10
):1337
–45
.14.
Mazen
I
, El-Gammal
M
, McElreavey
K
, Elaidy
A
, Abdel-Hamid
MS
. Novel AMH and AMHR2 mutations in two egyptian families with persistent müllerian duct syndrome
. Sex Dev
. 2017
;11
(1
):29
–33
.15.
McCann-Crosby
B
, Gunn
S
, Smith
EO
, Karaviti
L
, Hicks
MJ
. Association of immunohistochemical markers with premalignancy in Gonadal Dysgenesis
. Int J Pediatr Endocrinol
. 2015
;2015
(1
):14
.16.
Nayak
VJ
, Kamath
AS
, Krishnappa
MH
, Bylappa
SK
. Persistent mullerian duct syndrome: a case report and review of the literature
. Int J Appl Basic Med Res
. 2014
;4
(2
):125
–7
.17.
Neely
EK
, Hintz
RL
, Wilson
DM
, Lee
PA
, Gautier
T
, Argente
J
, . Normal ranges for immunochemiluminometric gonadotropin assays
. J Pediatr
. 1995
;127
(1
):40
–6
.18.
Nistal
M
, Paniagua
R
, González-Peramato
P
, Reyes-Múgica
M
. Perspectives in pediatric pathology, chapter 3. Testicular development from birth to puberty: systematic evaluation of the prepubertal testis
. Pediatr Dev Pathol
. 2015a
;18
(3
):173
–86
.19.
Nistal
M
, Paniagua
R
, González-Peramato
P
, Reyes-Múgica
M
. Perspectives in pediatric pathology, Chapter 5. Gonadal dysgenesis
. Pediatr Dev Pathol
. 2015b
;18
(4
):259
–78
.20.
Picard
JY
, Cate
RL
, Racine
C
, Josso
N
. The persistent müllerian duct syndrome: an update based upon a personal experience of 157 cases
. Sex Dev
. 2017
;11
(3
):109
–25
.21.
Richards
S
, Aziz
N
, Bale
S
, Bick
D
, Das
S
, Gastier-Foster
J
, . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
. Genet Med
. 2015
;17
(5
):405
–24
.22.
Saleem
M
, Ather
U
, Mirza
B
, Iqbal
S
, Sheikh
A
, Shaukat
M
, . Persistent mullerian duct syndrome: a 24-year experience
. J Pediatr Surg
. 2016 Oct
;51
(10
):1721
–4
.23.
Schteingart
HF
, Picard
JY
, Valeri
C
, Marshall
I
, Treton
D
, di Clemente
N
, . A mutation inactivating the distal SF1 binding site on the human anti-Müllerian hormone promoter causes persistent Müllerian duct syndrome
. Hum Mol Genet
. 2019
;28
(19
):3211
–8
.24.
Taketo
T
, Saeed
J
, Nishioka
Y
, Donahoe
PK
. Delay of testicular differentiation in the B6.YDOM ovotestis demonstrated by immunocytochemical staining for müllerian inhibiting substance
. Dev Biol
. 1991
;146
(2
):386
–95
.25.
Tanwar
PS
, Commandeur
AE
, Zhang
L
, Taketo
MM
, Teixeira
JM
. The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling
. Carcinogenesis
. 2012
;33
(12
):2351
–61
.26.
Vigier
B
, Watrin
F
, Magre
S
, Tran
D
, Garrigou
O
, Forest
MG
, . Anti-müllerian hormone and freemartinism: inhibition of germ cell development and induction of seminiferous cord-like structures in rat fetal ovaries exposed in vitro to purified bovine AMH
. Reprod Nutr Dev
. 1988
;28
(4B
):1113
–28
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
